Jean-Luc Lemercier

Jean-Luc Lemercier has been corporate vice president, EMEA (Europe, Middle East and Africa), Canada and Latin America since July 2017. Prior to assuming his current role, Lemercier served as vice president of transcatheter heart valves EMEA since 2008. Under his leadership at Edwards, the company successfully launched the SAPIEN transcatheter heart valve technology and built its leadership position in Europe. 

Before joining Edwards, Lemercier served various leadership roles with Johnson & Johnson Cordis from 1996-2008, including leader of the structural heart disease group in the United States; vice president of new business development in Europe and vice president of the Cordis cardiology division in Belgium; and general manager of Cordis France.  Lemercier has more than 30 years of medical device experience, beginning with Baxter in France, and held several sales and marketing management positions within Baxter Europe and the United States.

Lemercier holds a degree as a doctor in pharmacy from the Claude Bernard Lyon 1 University in Lyon, France.

He also serves as Chair of the Cardiovascular Sector Group of MedTech Europe

Despite significant advances in recent decades to improve cardiovascular care and reduce mortality, the burden of cardiovascular disease (CVD) remains greater than any other disease. A concerted effort is needed to ensure the voices of stakeholders are heard by policymakers and that cardiovascular health is prioritised accordingly. That is why we have come together just ahead of World Heart Day (29 September) to launch the European Alliance for Cardiovascular Health . Concerned about the current situation, – the European Society of Cardiology , the European Heart Network and MedTech Europe – invited other European organisations with a strong interest in cardiovascular health to join efforts to raise awareness of the burden of CVD. This has resulted in the European Alliance for Cardiovascular Health *, composed of 15 European organisations that bring together health professionals, patient advocates, industry experts, health insurers, NGOs, and others to ensure that Europe’s response to CVD matches the scale of the collective challenge we face. Together, we call for resolute action by European decision-makers to improve cardiovascular health through a dedicated EU policy plan . Burden of cardiovascular disease augmented by the pandemic The data on the burden of CVD is striking. CVD remains the leading cause of death in the EU contributing to 36% of all deaths compared to 26% for cancer. CVD impacts people of all ages, with CVD accounting for a significant proportion of premature deaths (CVD mortality before age 65 is 24% in men and 17% in women). We were aware of this high burden of CVD before COVID-19 swept across Europe in 2020. However, the pandemic has exacerbated the CVD epidemic and clearly illustrated the vulnerability of patients with CVD. We know now that the SARS-CoV-2 virus damages the heart and vascular system, and that these mechanisms may explain the extremely...
Did you know that every day, some 5,000 people die from cardiovascular diseases (CVDs), amounting to 1.8 million deaths every year ? This, unfortunately, makes cardiovascular disease - including heart failure, stroke-related atrial fibrillation, heart valve disease and coronary heart disease - the number one killer in Europe. The COVID-19 pandemic has radically changed the way we live, work, and care for patients. Whilst we are still in the midst of overcoming the challenges posed by the pandemic, one uncomfortable truth is becoming clear: people affected by cardiovascular disease have been hit the hardest by COVID-19 – whether it was by discontinuity of care or because cardiovascular disease constitutes the leading co-morbidity in COVID-19 deaths (65%) . In addition, mounting evidence shows that COVID-19 sufferers can develop heart complications further on. There is reason enough to act to improve the cardiovascular health of our citizens. After working in MedTech for many years, I can say that the necessary technologies and innovations often already exist. Our innovative industry provides concrete solutions to reduce the burden of cardiovascular disease on individuals, families, carers, and the wider economy. These innovations, which span the full spectrum of patient care from diagnosis to cure, save lives and add tremendous value to European society. What we lack is the comprehensive policy framework that enables better collaboration between stakeholders to drive solutions and innovations towards the patients that need them. Today, the EU has a unique opportunity to make a difference for people with cardiovascular disease, thanks to the priority given to healthcare on the citizens' agenda and the unprecedented funding provided by the EU4Health, Horizon Europe and Next Generation Recovery funds. By implementing an EU Action Plan with the right framework and incentives, we can bring together EU players, Member States and key stakeholders to save...
The unprecedented COVID-19 has fundamentally shifted society’s and government’s attention and prioritisation of healthcare. Never has health topped our agenda as much as today - as an individual trying to stay healthy, as healthcare professional and facility trying to deliver a high quality of care, as industry trying to deliver the best innovations to improve care, or as government are working to sustain healthcare system at large. Now that we are a few months into the management of the pandemic, we have had to learn the hard way that COVID-19 has unfortunately had significant implications on the cardiovascular care of patients. Not only have we learned that those living with pre-existing cardiovascular diseases who contract COVID-19 are at an increased risk of health deterioration and death: 65% of all COVID-19 deaths recorded were associated with a cardiovascular comorbidity. [1] With such startling figures, the treatment of cardiovascular patients should continue to top the priority list for care so that we can prevent avoid further deterioration in health or even death. However, we have seen the opposite happen as we have witnessed severe disruptions in care for these patients since the start of the COVID-19 pandemic. There has been a 50% decrease in the number of people presenting themselves at hospitals and other healthcare facilities, with symptoms of heart-related symptoms. [2] So whilst we are still fighting the pandemic, let us take the occasion of World Heart Day today to remind us of the importance of the prevention, detection and early diagnosis of cardiovascular disease, as well as the efficient management when they occur. With European and national recovery and resilience plans in the making, governments have a unique opportunity and responsibility to craft investments in healthcare in a way that makes the system more sustainable, equitable and efficient. Many healthcare...
Even in 2019, cardiovascular diseases (CVD) remain the number 1 killer globally, accounting for almost 2 million deaths in the EU alone every year. These diseases are linked to huge inequalities, with more cardiovascular-related deaths in women than men, and more CVD-related deaths in middle-income than high-income countries, as a recent study from the European Society of Cardiology shows. Meanwhile, the burden of cardiovascular diseases amounts to €210 billion per year, due to healthcare costs, productivity loss, and informal care by caregivers. As Chair of the MedTech Europe Cardiovascular Sector Group, I and our group believe that time is running out to ensure concrete policy and regulatory action that will relieve the burden of cardiovascular disease, for once and for all. It is only by working together - industry, public authorities, and policy-makers,- with patients and all stakeholders that we can achieve this goal, and help to keep workers, and citizens of all ages, in good health and out of hospital, regardless of gender, income, or country. With the EU Institutions working up their 2020 – 2024 agenda, our group believes that it is the optimal time to call for the 3 following common actions that could help to achieve that goal: 1. Better understand the burden of cardiovascular diseases and facilitate access to comprehensive and regular checks. Most of these diseases have much better prognosis, higher treatment success and lower social cost when diagnosed and treated early, so there is a real business and societal case to introduce such checks for populations at risk. 2. Improve quality of life of patients suffering from cardiovascular diseases and improve efficiencies in care through fast access to innovation. Today, too many patients with unmet medical needs do not have access to the treatment they deserve because of inefficiencies in the access and...
heart innovation health
Given that the number of Europeans aged over 65 will double in the next 50 years, and the number of over 80 year olds will almost triple, it follows that keeping this age group in good health is a particular priority. However, European healthcare systems are at a tipping point, driven by the increasing burden of providing world-class care at a time when the long-term effects of austerity measures are putting pressure on healthcare spending. Keeping these challenges in mind, Heart Month is a good time to reflect on how breakthrough innovation in the area of healthcare can contribute to building a cohesive, prosperous and successful Europe. I spoke recently at a Friends of Europe event to discuss the McKinsey Institute report, Europe 2030 - Towards a Renewed Social Contract . McKinsey proposed that Security, Prosperity and Sustainability should be three pillars of this renewed social contract. I argued that we need to add a fourth pillar of Health, built upon disruptive technological innovation and a commitment to positive ageing. I believe that good health is at the cornerstone of a strong and prosperous Europe. It is also a reciprocal responsibility; we citizens should take personal responsibility for our own health and, in return, those running our healthcare systems should provide the best treatment for us when we are ill. However, the impact of disruptive technology in improving healthcare system sustainability for the benefit of patients is not fully appreciated in Europe. This innovation can transform medical practice, with faster procedures and reduced lengths of hospital stay. It can lead, as a consequence, to more patients benefiting; and it can even potentially reduce long-term costs, both within the healthcare system and in social care for older people. We need to rekindle our openness to healthcare innovation in Europe. Our health...